AxoGen (NASDAQ:AXGN) Price Target Raised to $60.00

AxoGen (NASDAQ:AXGN) had its price target increased by Truist Financial from $53.00 to $60.00 in a research report released on Thursday,Benzinga reports. They currently have a buy rating on the medical equipment provider’s stock.

Other equities analysts also recently issued reports about the company. Wall Street Zen downgraded AxoGen from a “buy” rating to a “hold” rating in a research report on Saturday, September 26th. Barclays upped their target price on AxoGen from $50.00 to $60.00 and gave the company an “overweight” rating in a report on Thursday. Canaccord Genuity Group increased their target price on shares of AxoGen from $50.00 to $55.00 and gave the company a “buy” rating in a research report on Thursday, July 30th. Lake Street Capital restated a “buy” rating on shares of AxoGen in a report on Monday, October 5th. Finally, Citigroup restated a “market outperform” rating on shares of AxoGen in a report on Thursday, July 30th. Thirteen analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, AxoGen presently has an average rating of “Moderate Buy” and an average target price of $57.92.

AxoGen Stock Performance

NASDAQ AXGN opened at $49.37 on Thursday. The company has a market capitalization of $2.95 billion, a price-to-earnings ratio of -75.95 and a beta of 1.17. The company has a quick ratio of 5.04, a current ratio of 12.02 and a debt-to-equity ratio of 0.04. AxoGen has a twelve month low of $21.68 and a twelve month high of $52.91. The stock has a fifty day simple moving average of $42.86 and a 200 day simple moving average of $39.45.

AxoGen (NASDAQ:AXGN) last announced its earnings results on Wednesday, October 28th. The medical equipment provider reported $0.21 EPS for the quarter, topping the consensus estimate of $0.13 by $0.08. AxoGen had a negative return on equity of 5.35% and a negative net margin of 11.96%. The firm had revenue of $75.83 million for the quarter, compared to the consensus estimate of $73.45 million. Sell-side analysts expect that AxoGen will post -0.44 EPS for the current year.

Insiders Place Their Bets

In other news, Director Amy Wendell sold 13,353 shares of AxoGen stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $48.42, for a total value of $646,552.26. Following the completion of the transaction, the director directly owned 107,976 shares of the company’s stock, valued at approximately $5,228,197.92. This trade represents a 11.01% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Marc Began sold 67,500 shares of AxoGen stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $47.34, for a total value of $3,195,450.00. Following the completion of the transaction, the executive vice president directly owned 50,135 shares of the company’s stock, valued at approximately $2,373,390.90. This trade represents a 57.38% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 98,503 shares of company stock valued at $4,656,947. 2.44% of the stock is currently owned by insiders.

Institutional Investors Weigh In On AxoGen

Several large investors have recently added to or reduced their stakes in the business. VIRGINIA RETIREMENT SYSTEMS ET Al increased its holdings in AxoGen by 46.0% in the third quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 30,150 shares of the medical equipment provider’s stock worth $1,264,000 after purchasing an additional 9,500 shares in the last quarter. Sterling Capital Management LLC lifted its stake in AxoGen by 858.9% in the third quarter. Sterling Capital Management LLC now owns 1,774 shares of the medical equipment provider’s stock valued at $74,000 after buying an additional 1,589 shares during the period. State of Alaska Department of Revenue lifted its stake in AxoGen by 16.9% in the third quarter. State of Alaska Department of Revenue now owns 2,833 shares of the medical equipment provider’s stock valued at $118,000 after buying an additional 409 shares during the period. Artemis Investment Management LLP boosted its holdings in shares of AxoGen by 27.5% during the 3rd quarter. Artemis Investment Management LLP now owns 1,780,992 shares of the medical equipment provider’s stock worth $74,659,000 after buying an additional 384,200 shares in the last quarter. Finally, Sequoia Financial Advisors LLC bought a new position in shares of AxoGen during the 2nd quarter worth approximately $272,000. Institutional investors and hedge funds own 80.29% of the company’s stock.

AxoGen News Roundup

Here are the key news stories impacting AxoGen this week:

• Positive Sentiment: Strong Q3 execution and higher guidance: AxoGen reported 26% revenue growth and 45% adjusted EBITDA growth for the third quarter of 2026. Management maintained a target of at least $290 million in 2026 sales and expects gross margin of 73% or higher, reinforcing the company’s growth and operating-leverage story. AxoGen Third-Quarter Earnings Results
• Positive Sentiment: Analysts raised their targets: Canaccord Genuity increased its price target to $60 from $55 and maintained a Buy rating. Truist also raised its target to $60 from $53, while Wells Fargo increased its target to $56 from $48 and kept an Overweight rating. HC Wainwright lifted its target to $56 from $53 and retained a Buy rating. These revisions indicate improving confidence in AxoGen’s earnings outlook. Truist AxoGen Price Target Update
• Positive Sentiment: BioCircuit acquisition expands the opportunity: An investment analysis characterized AxoGen as evolving toward a leading procedural platform in peripheral nerve repair. The planned $200 million BioCircuit, or NerveTape, acquisition is intended to reduce technical barriers for surgeons, broaden the addressable market and be accretive at an estimated 5.9 times 2027 sales. AxoGen Taking the Friction Out of Nerve Repair
• Neutral Sentiment: Valuation remains an investor debate: Coverage is focused on whether AXGN’s growth prospects justify its elevated valuation after its substantial advance. The stock’s performance relative to other medical companies may attract momentum investors, but also raises the risk that much of the near-term optimism is already reflected in the share price. Does AxoGen Have More Upside?
• Negative Sentiment: Profitability and execution risks remain: Despite improving adjusted EBITDA, AxoGen continues to report negative net income and analysts expect a full-year loss. Investors must also weigh acquisition integration, dilution and the company’s premium valuation against the possibility of slower growth.

AxoGen Company Profile

AxoGen, Inc (NASDAQ: AXGN) is a medical technology company focused on developing and commercializing products for the repair and regeneration of peripheral nerves. Its technologies are designed to help restore sensory and motor function following traumatic injuries, surgical procedures, and other conditions affecting peripheral nerves.

The company’s product portfolio includes Avance Nerve Graft, a processed human nerve allograft used to bridge gaps in damaged nerves without requiring tissue to be taken from another part of the patient’s body.